Physician profile

Chad E Allen

Nurse Practitioner · High Point, NC

NPI 1780293266

$5,748.65

in general payments reported to CMS, 2019-2025

42 companies · $594 in 2025

The $594 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,457.63

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $1,290.92 2021-2025 Wegovy, Ozempic, Rybelsus
Abbvie INC. $1,257.12 2021-2025
Astrazeneca Pharmaceuticals Lp $574.93 2021-2025 Farxiga, Airsupra, Breztri
Glaxosmithkline, LLC. $376.98 2021-2024 Trelegy Ellipta, Shingrix, Arexvy
Lilly USA, LLC $339.94 2021-2025 Mounjaro, Jardiance, Emgality
Astellas Pharma US INC $226.89 2023-2025 Veozah, Myrbetriq
Boehringer Ingelheim Pharmaceuticals, INC. $208.88 2023-2024 Jardiance
Dexcom, INC. $127.31 2023-2024 Dexcom G6 Transmitter
Bayer Healthcare Pharmaceuticals INC. $114.48 2022-2025
Biohaven Pharmaceutical Holding Company Ltd. $97.00 2022
Ironwood Pharmaceuticals, INC $95.00 2022-2024
Biohaven Pharmaceuticals, INC. $86.24 2021
Sanofi-Aventis U.S. LLC $82.02 2023
Lundbeck LLC $81.24 2023-2024 Vyepti
Amgen INC. $58.87 2022-2025 Krystexxa, Otezla, Repatha
Show all 42 companies
CompanyGeneral paymentsYearsTop products
Hologic Sales and Service, LLC $54.06 2023-2024 Thinprep 2000 Processor, Aptima, Affirm Prone Biopsy System
Genentech USA, INC. $51.73 2021
Novartis Pharmaceuticals Corporation $47.53 2023
Pfizer INC. $47.52 2023-2024
Mylan Specialty L.P. $43.30 2024 Yupelri
Abbott Laboratories $37.62 2024 Freestyle Libre 3
Vanda Pharmaceuticals INC. $36.83 2024 Hetlioz, Fanapt
Idorsia Pharmaceuticals US INC $35.52 2023 Quviviq
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $34.88 2025 Caplyta
Otsuka America Pharmaceutical, INC. $30.13 2025 Rexulti
Takeda Pharmaceuticals U.S.A., INC. $28.87 2021
Amarin Pharma, INC. $27.75 2021
Grt US Holding, INC. $26.41 2021
Indivior INC. $24.50 2025 Sublocade
Exact Sciences Corporation $20.52 2025 The Cologuard Plus Collection Kit
Corcept Therapeutics $18.76 2023 Korlym
Forte Bio-Pharma LLC $17.48 2022
Mannkind Corporation $16.42 2023 Afrezza
Esperion Therapeutics, INC. $16.03 2021
Sumitomo Pharma America, INC. $16.02 2025 Gemtesa
Collegium Pharmaceutical, INC. $15.69 2022
Corium, LLC $14.98 2023 Adlarity
Inspire Medical Systems, INC. $14.65 2025 Inspire
Phathom Pharmaceuticals, INC. $13.99 2025 Voquezna
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $13.92 2022
Shield Therapeutics INC $13.53 2025
Orexo US, INC. $12.19 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Chad E Allen

$5,748.65

in general payments reported 2019-2025

Years
2021-2025
Top company
Novo Nordisk INC
Context
The $594 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).

https://glasscript.com/doctor/11067036/chad-e-allen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.